CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis

Rampotas A., Wong Z., Gannon I., Brierley C., Shen Y., Benlabiod C., Chee A., Khan S., Hayder N., Cheung G., Mitsikakou M., Murphy E., Ferrari M., Bulek A., Rodriquez-Romera A., Murphy L., Olijnik A-A., Rodriguez-Justo M., Marty C., Hitchcock I., ROYSTON D., Mead A., Khan AO., Lambert J., Roddie C., Psaila B., Pule M.

DOI

10.64898/2026.01.28.702220

Type

Preprint

Publication Date

2026-02-01T00:00:00+00:00

Keywords

32 Biomedical and Clinical Sciences, 3211 Oncology and Carcinogenesis, 3204 Immunology, Clinical Trials and Supportive Activities, Biotechnology, Cancer, Hematology, Gene Therapy, Stem Cell Research - Nonembryonic - Non-Human, Clinical Research, Gene Therapy Clinical Trials, Immunotherapy, Stem Cell Research, Orphan Drug, Genetics, Stem Cell Research - Nonembryonic - Human, Rare Diseases, 2.1 Biological and endogenous factors, 5.1 Pharmaceuticals, 5.2 Cellular and gene therapies, Cancer

Permalink More information Close